[1] Pradat P, Virlogeux V, Trepo E. Epidemiology and elimination of HCV-related liver disease. Viruses,2018,10:1.
[2] Tapper EB,Afdhal NH. Is 3 the new1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat,2013,20:669-677.
[3] Messina JP,Humphreys I,Flaxman A,et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology,2015,61:77-87.
[4] Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated ?brosis progression in chronic hepatitis C. J Hepatol,2009,51: 655-666.
[5] Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-31). Hepatology, 2016,63:1430-1441.
[6] Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology, 2015,61:1127-1135.
[7] Menzo SL, Biagi E, Nuzzo MD, et al.SVR 24 achievement two weeks after a tripled dose of daclatasvir in an HCV genotype 3 patient. Hepatology, 2018,17:661-664.
[8] Tao YC, Deng R, Wang ML, et al. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.Virol J,2018,15:150-158. |
